Please use this identifier to cite or link to this item:
https://scidar.kg.ac.rs/handle/123456789/8466
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.rights.license | openAccess | - |
dc.contributor.author | Borovcanin N. | - |
dc.contributor.author | Ristanović E. | - |
dc.contributor.author | Todorovic, Milos | - |
dc.contributor.author | Borovcanin, Milica | - |
dc.contributor.author | Jovanovic, Mirjana | - |
dc.contributor.author | Balint B. | - |
dc.date.accessioned | 2020-09-19T15:50:11Z | - |
dc.date.available | 2020-09-19T15:50:11Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0042-8450 | - |
dc.identifier.uri | https://scidar.kg.ac.rs/handle/123456789/8466 | - |
dc.description.abstract | © 2019 Inst. Sci. inf., Univ. Defence in Belgrade. All rights reserved. Background/Aim: Intravenous drug users (IDUs) are still a high risk-group for cross-reacting blood-borne infections, for vertical pathogen transmission as well as for potentially blood/plasma donation (especially as paid donors). The aim of our study was to establish the profile of opiate addict and prevalence of blood-borne pathogens - Hepatitis B virus (HBV), Hepatitis C virus (HCV) and Human Immunodeficiency Virus (HIV) among 99 patients on substitution therapy with methadone and buprenorphine from Šumadia District. Methods: The Treatment Demand Indicator (TDI) of Pompidou-questionnaire was used to assess the history of drug abuse and risk behavior. All blood samples were tested for HBV surface antigen (HBsAg), anti-HCV antibody (anti-HCV) and HIV antigen/antibody (HIV-Ag/Ab) by Enzyme-Linked ImmunoSorbent Assay (ELISA) or Chemiluminescent Immuno-Assay (CIA). Investigations were also performed for HBV, HCV and HIV by molecular testing - Polymerase Chain Reaction (PCR) method. Results: The majority of patients were males (81.8%), median age 32 (19-57) years, lived in a city (99%), unemployed (58.6%), with finished secondary school (67.7%), unsafe injecting practices (34.3%) and never previously tested for HBV (39.4%), HCV (36.4%) nor HIV (28.3%); only 4% of them previously got HBV-vaccine. The complementary testing resulted with following results: HBV ELISA/CIA and PCR negativity for 66 patients and positive results (by ELISA/CIA and PCR) for 19 patients. However, a difference was observed in the ELISA/CIA-negative/PCR-positive result for 12 and ELISA/CIA-positive/PCR-negative for two patients respectively. Further, the negative results for HCV (ELISA/CIA and PCR testing) were found in 15 IDUs and positive results (using both methods) were found in 58 patients. Different results for ELISA/CIA-negative / PCR-positive results were found in 11 IDUs and ELISA/CIA-positive/PCR - negative results were found in 15 patients. All investigated IDUs were negative for HIV (ELISA/CIA and PCR testing) and for pathogens of opportunistic infection (Cryptococcus neoformans; Pneumocystis carinii; PCR testing), as well as for West Nile Virus (PCR testing). Just one IDU was positive for syphilis (ELISA and confirmatory testing). Conclusion: Our study demonstrated that the positivity for HBV and HCV is still very high (33.4% and 84.8%, respectively) in IDUs. Thus, we suggest that drug users have to be periodically screened using a complementary serological/molecular testing - concerning differences/discrepancies in the results obtained using these methods. | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.source | Vojnosanitetski Pregled | - |
dc.title | The use of complementary serological and molecular testing for blood-borne pathogens and evaluation of socio-demographic characteristics of intravenous drug users on substitution therapy from Šumadia district of Serbia | - |
dc.type | article | - |
dc.identifier.doi | 10.2298/VSP170814129B | - |
dc.identifier.scopus | 2-s2.0-85079414338 | - |
Appears in Collections: | Faculty of Medical Sciences, Kragujevac |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
10.2298-VSP170814129B.pdf | 442.64 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License